Crispr Therapeutics (NASDAQ:CRSP) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Friday, BidAskClub reports.

Other research analysts also recently issued reports about the company. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Finally, Oppenheimer lifted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $69.54.

Shares of CRSP stock opened at $65.36 on Friday. The stock’s 50 day simple moving average is $58.93 and its 200 day simple moving average is $48.44. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $74.00. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of -19.00 and a beta of 3.31.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. On average, analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.

In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock worth $3,620,760. Company insiders own 21.40% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Benjamin Edwards Inc. grew its holdings in shares of Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after purchasing an additional 268 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Crispr Therapeutics by 13.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after purchasing an additional 343 shares in the last quarter. Traynor Capital Management Inc. grew its holdings in shares of Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after purchasing an additional 375 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Crispr Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after purchasing an additional 386 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Crispr Therapeutics by 7.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock worth $331,000 after purchasing an additional 467 shares in the last quarter. 49.82% of the stock is currently owned by institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: How is inflation measured?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)




Source link